SELLAS Life Sciences Group, Inc. Additional Paid in Capital, Common Stock
SELLAS Life Sciences Group, Inc. (SLS) had Additional Paid in Capital, Common Stock of $430.64 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $430.64M.
- 2026-03-31: Additional Paid in Capital, Common Stock $390.79M.
- 2025-12-31: Additional Paid in Capital, Common Stock $345.84M.
- 2025-09-30: Additional Paid in Capital, Common Stock $312.95M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $430.64M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $390.79M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $345.84M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $312.95M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $286.68M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $281.69M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $257.58M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $257.27M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $237.19M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $236.49M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $209.26M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $205.28M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $204.68M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $204.17M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $184.75M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $183.38M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $182.82M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $159.37M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $158.95M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $158.61M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $158.33M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $149.05M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $145.86M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $122.13M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $113.49M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $113.34M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $107.24M 10-K · filed 2021-03-23 | $107.23M 10-K · filed 2020-03-13 |
| 2019-09-30 | $104.36M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $103.85M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $89.34M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $87.10M 10-K · filed 2020-03-13 | $87.10M 10-K · filed 2019-03-22 |
| 2018-09-30 | $86.99M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $65.76M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $60.86M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $56.25M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $347.61M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $346.03M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $345.69M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $25.43M 10-K · filed 2018-04-13 | $335.42M 10-K · filed 2017-03-15 |
| 2016-09-30 | $325.18M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $314.64M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $312.12M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $296.73M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $295.96M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $294.88M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $288.94M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $256.38M 10-K/A · filed 2016-04-15 | |
| 2014-09-30 | $242.22M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $233.50M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $231.75M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $188.60M 8-K · filed 2015-12-04 | |
| 2013-09-30 | $167.11M 10-Q/A · filed 2013-11-07 | |
| 2013-06-30 | $136.65M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $132.75M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $132.17M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $116.45M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $115.14M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $85.26M 10-Q · filed 2012-05-14 | |
| 2011-12-31 | $81.18M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $77.37M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $74.32M 10-Q/A · filed 2011-10-28 | $74.67M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $62.02M 10-K · filed 2012-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |